ctDNA Carves a Precise Path for Early-Stage NSCLC Management.
- Published in:
- OncologyLive, 2024, v. 25, n. 11, p. 64
- By:
- Publication type:
- Article
Works matching IS 23745347 AND DT 2024 AND VI 25 AND IP 11
Results: 18
1
2
Experts Delve Into Case-Based Discussions in Locally Advanced Lung Cancer.
- Published in:
- OncologyLive, 2024, v. 25, n. 11, p. 59
- By:
- Publication type:
- Article
3
Adding Chemotherapy to Frontline Osimertinib Is Under Debate in EGFR-Mutated NSCLC..
- Published in:
- OncologyLive, 2024, v. 25, n. 11, p. 56
- By:
- Publication type:
- Article
4
ODAC Weighs In on the Future of Perioperative Trial Designs in Resectable NSCLC.
- Published in:
- OncologyLive, 2024, v. 25, n. 11, p. 52
- By:
- Publication type:
- Article
5
Society Moves Toward a Science of Scaling Medical Artificial Intelligence.
- Published in:
- OncologyLive, 2024, v. 25, n. 11, p. 50
- By:
- Publication type:
- Article
6
AI Is Poised to Influence Several Areas of Cancer Care With Some Fine-Tuning.
- Published in:
- OncologyLive, 2024, v. 25, n. 11, p. 48
- By:
- Publication type:
- Article
7
FROM BENCH TO BEDSIDE: HIF-2α Inhibition in RCC.
- Published in:
- OncologyLive, 2024, v. 25, n. 11, p. 46
- By:
- Publication type:
- Article
8
Rezatapopt Takes Aim at Previously Untargetable TP53 Allele in Advanced Solid Tumors.
- Published in:
- OncologyLive, 2024, v. 25, n. 11, p. 40
- By:
- Publication type:
- Article
9
PARP1-Selective Inhibitors Generate Excitement in Solid Tumors.
- Published in:
- OncologyLive, 2024, v. 25, n. 11, p. 37
- By:
- Publication type:
- Article
10
Next Generation of CDK Inhibitors Are Breaking Ground in HER2–Breast Cancer.
- Published in:
- OncologyLive, 2024, v. 25, n. 11, p. 25
- By:
- Publication type:
- Article
11
HER2-Directed ADCs Spread Like Wildfire Across the Spectrum of Solid Malignancies.
- Published in:
- OncologyLive, 2024, v. 25, n. 11, p. 16
- By:
- Publication type:
- Article
12
Adagrasib/Cetuximab Combo Marks Beginning of RAS-Targeting Era in CRC.
- Published in:
- 2024
- By:
- Publication type:
- Interview
13
FDA Advises Against Accelerated Approval of Botensilimab Plus Balstilimab in Relapsed/Refractory MSS CRC.
- Published in:
- OncologyLive, 2024, v. 25, n. 11, p. 12
- Publication type:
- Article
14
Crovalimab Receives Stamp of Approval for Paroxysmal Nocturnal Hemoglobinuria.
- Published in:
- OncologyLive, 2024, v. 25, n. 11, p. 12
- Publication type:
- Article
15
Pembrolizumab Plus Chemo Gets Go-Ahead for Advanced/Recurrent Endometrial Carcinoma.
- Published in:
- OncologyLive, 2024, v. 25, n. 11, p. 12
- Publication type:
- Article
16
Blinatumomab Receives Approval for CD19+ B-ALL in the Consolidation Phase.
- Published in:
- OncologyLive, 2024, v. 25, n. 11, p. 12
- Publication type:
- Article
17
THE SCIENTIFIC VALIDITY OF PEER-REVIEWED PUBLICATIONS: A Concerning Situation With Implications for Oncology.
- Published in:
- OncologyLive, 2024, v. 25, n. 11, p. 10
- By:
- Publication type:
- Article
18
MJH Reflects on Innovations in Oncology With 25th Anniversary.
- Published in:
- OncologyLive, 2024, v. 25, n. 11, p. 8
- By:
- Publication type:
- Article